Methods for selecting and treating patients with active Systemic Lupus Erythematosus (SLE) that are predicted to have an increased likelihood of having a positive response to a treatment with a safe and effective amount of an anti-IL-12/IL-23p40 antibody or an anti-IL-23 antibody, e.g., informs on what patients to treat with the anti-IL-12/IL-23p40 antibody ustekinumab.

Methods for predicting the development of sepsis in a subject at risk for developing sepsis are provided. In one method, features in a biomarker profile of the subject are evaluated. The subject is likely to develop sepsis if these features satisfy a particular value set. Methods for predicting the development of a stage of sepsis in a subject at risk for developing a stage of sepsis are provided. In one method, a plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to have the stage of sepsis if these feature values satisfy a particular value set. Methods of diagnosing sepsis in a subject are provided. In one such method, a plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to develop sepsis when the plurality of features satisfies a particular value set.

Methods for predicting the development of sepsis in a subject at risk for developing sepsis are provided. In one method, features in a biomarker profile of the subject are evaluated. The subject is likely to develop sepsis if these features satisfy a particular value set. Methods for predicting the development of a stage of sepsis in a subject at risk for developing a stage of sepsis are provided. In one method, a plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to have the stage of sepsis if these feature values satisfy a particular value set. Methods of diagnosing sepsis in a subject are provided. In one such method, a plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to develop sepsis when the plurality of features satisfies a particular value set.

The present invention includes a method for analyzing RNA fragments. In one aspect, the present invention includes a method of identifying a subject in need of therapeutic intervention to treat a disease or condition, disease recurrence, or disease progression comprises characterizing the identity of rRNA fragments. The invention also includes diagnosing, identifying or monitoring a disease or condition, and a method for identifying rRNA fragments. The invention also includes diagnosing, identifying or monitoring a glaucoma in a subject in need thereof by characterizing the identity of rRNA or tRNA fragments.

The present invention includes a method for analyzing RNA fragments. In one aspect, the present invention includes a method of identifying a subject in need of therapeutic intervention to treat a disease or condition, disease recurrence, or disease progression comprises characterizing the identity of rRNA fragments. The invention also includes diagnosing, identifying or monitoring a disease or condition, and a method for identifying rRNA fragments. The invention also includes diagnosing, identifying or monitoring a glaucoma in a subject in need thereof by characterizing the identity of rRNA or tRNA fragments.

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

The present invention provides a method of assessing type 2 diabetes susceptibility and/or predicting treatment responsiveness in a human subject, the method comprising determining the identity of at least one allele at each of three or more positions of single nucleotide polymorphism (SNP) selected from the group consisting of: SLC16A11-rs75493593; HNF1A-rs483353044; TCF7L2-rs7903146; CDKN2A/B-rs10811661; CDKAL1-rs7756992; SLC30A8-rs3802177; IGF2BP2-rs4402960; FTO-rs9936385; PPARG-rs1801282; HHEX/IDE-rs1111875; ADCYS-rs11717195; JAZF1-rs849135; WSF1-rs4458523; INS-IGF2-rs149483638; KCNQ1-rs2237897; and KCNJ11-rs5219, and/or an SNP in linkage disequilibrium with any one of said SNPs at r.sup.2>0.8. Also provided are a genotyping tool and a type 2 diabetes risk assessment system for use in the method of the invention.

The present invention provides a method of assessing type 2 diabetes susceptibility and/or predicting treatment responsiveness in a human subject, the method comprising determining the identity of at least one allele at each of three or more positions of single nucleotide polymorphism (SNP) selected from the group consisting of: SLC16A11-rs75493593; HNF1A-rs483353044; TCF7L2-rs7903146; CDKN2A/B-rs10811661; CDKAL1-rs7756992; SLC30A8-rs3802177; IGF2BP2-rs4402960; FTO-rs9936385; PPARG-rs1801282; HHEX/IDE-rs1111875; ADCYS-rs11717195; JAZF1-rs849135; WSF1-rs4458523; INS-IGF2-rs149483638; KCNQ1-rs2237897; and KCNJ11-rs5219, and/or an SNP in linkage disequilibrium with any one of said SNPs at r.sup.2>0.8. Also provided are a genotyping tool and a type 2 diabetes risk assessment system for use in the method of the invention.

Embodiments of the invention describe to methods of diagnosing, classifying, and/or identifying a patient's risk of developing graft versus host disease, including severe or lethal graft versus host disease, after receiving hematopoietic cellular transplantation, a transfusion or a transplantation, but before the onset of clinical symptoms.

Embodiments of the invention describe to methods of diagnosing, classifying, and/or identifying a patient's risk of developing graft versus host disease, including severe or lethal graft versus host disease, after receiving hematopoietic cellular transplantation, a transfusion or a transplantation, but before the onset of clinical symptoms.